Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis

Archives of Ophthalmology

Volumn 124, Issue 7, 2006, Pages 1012-1018

  Mruthyunjaya, Prithvi ^a   Khalatbari, Dara ^a   Yang, Ping ^a   Stinnett, Sandra ^a   Tano, Ryotaro ^a   Ashton, Paul ^b   Guo, Hong ^b   Nazzaro, Marty ^b   Jaffe, Glenn J ^a  

^a DUKE UNIVERSITY EYE CENTER   (United States)

^b Control Delivery Systems Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOCINOLONE ACETONIDE; TUBERCULIN;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG INHIBITION; DRUG RELEASE; ELECTRORETINOGRAPHY; EYE INFLAMMATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE COUNT; NONHUMAN; PRIORITY JOURNAL; RABBIT; SUSTAINED RELEASE PREPARATION; TISSUE SECTION; UVEITIS; VITREOUS BODY; VITREOUS OPACITY;

ANIMALS; AQUEOUS HUMOR; DISEASE MODELS, ANIMAL; DRUG IMPLANTS; ELECTRORETINOGRAPHY; EYE PROTEINS; FLUOCINOLONE ACETONIDE; GLUCOCORTICOIDS; LEUKOCYTE COUNT; RABBITS; TREATMENT OUTCOME; UVEITIS; VITREOUS BODY;

EID: 33745847551     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.124.7.1012     Document Type: Article

References (22)

1. Lafranco Dafflon M, Tran VT, Guex-Crosier Y, Herbort CP. Posterior sub-Tenon's steroid injections for the treatment of posterior ocular inflammation: indications, efficacy and side effects. Graefes Arch Clin Exp Ophthalmol. 1999;237:289-295.
2. Ozerdem U, Levi L, Cheng L, Song MK, Scher C, Freeman WR. Systemic toxicity of topical and periocular corticosteroid therapy in an 11-year-old male with posterior uveitis. Am J Ophthalmol. 2000;130:240-241.
3. Moshfeghi DM, Lowder CY, Roth DB, Kaiser PK. Retinal and choroidal vascular occlusion after posterior sub-tenon triamcinolone injection. Am J Ophthalmol. 2002;134:132-134.
4. Moorthy RS, Mermoud A, Baerveldt G, Minckler DS, Lee PP, Rao NA. Glaucoma associated with uveitis. Surv Ophthalmol. 1997;41:361-394.
5. Gomez-Ulla F, Gonzalez F, Ruiz-Fraga C. Unintentional intraocular injection of corticosteroids. [comment]. Acta Ophthalmol (Copenh). 1993;71:419-421.
6. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, ffytche TJ, Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology. 2001;108:765-772.
7. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol. 2001;29:2-6.
8. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 2003;136:791-796.
9. Tamesis RR, Rodriguez A, Christen WG, Akova YA, Messmer E, Foster CS. Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease. Ophthalmology. 1996;103:768-775.
10. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492-513.
11. Cheng CK, Berger AS, Pearson PA, Ashton P, Jaffe GJ. Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis. Invest Ophthalmol Vis Sci. 1995;36:442-453.
12. Jaffe GJ, Ben-Nun J, Guo H, Dunn JP, Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000;107:2024-2033.
13. Jaffe GJ, Pearson PA, Ashton P. Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. Retina. 2000;20:402-403.
14. Jaffe GJ, Yang CS, Wang XC, Cousins SW, Gallemore RP, Ashton P. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology. 1998;105:46-56.
15. Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butner Z, Ashton P. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology. 2005;112:1192-1198.
16. Jaffe GJ, Yang CH, Guo H, Denny JP, Lima C, Ashton P. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci. 2000;41:3569-3575.
17. Jaffe GJ. Fluocinolone acetonide intravitreal implant to treat posterior uveitis: 2-year results of a multicenter clinical trial. Paper presented at: 77th Annual Meeting of the Association for Research in Vision and Ophthalmology; May 3, 2005; Fort Lauderdale, Fla.
18. Jaffe GJ, Yang CS, Wang XC, Cousins SW, Gallemore RP, Ashton P. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology. 1998;105:46-56.
19. Verma MJ, Mukaida N, Vollmer-Conna U, Matsushima K, Lloyd A, Wakefield D. Endotoxin-induced uveitis is partially inhibited by anti-IL-8 antibody treatment. Invest Ophthalmol Vis Sci. 1999;40:2465-2470.
20. Driot JY, Novack GD, Rittenhouse KD, Milazzo C, Pearson PA. Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther. 2004;20:269-275.
21. Knepper PA, Breen M, Weinstein HG, Blacik JL. Intraocular pressure and glycosaminoglycan distribution in the rabbit eye: effect of age and dexamethasone. Exp Eye Res. 1978;27:567-575.
22. Cousins SW. T cell activation within different intraocular compartments during experimental uveitis. Dev Ophthalmol. 1992;23:150-155.